FDA ODD given to Plus Therapeutics’ injectable radiotherapy
The FDA has granted orphan drug designation to Plus Therapeutics’ injectable radiotherapy, Rhenium (186Re) Obisbemeda.
The FDA has granted orphan drug designation to Plus Therapeutics’ injectable radiotherapy, Rhenium (186Re) Obisbemeda.
What's Your Reaction?
